Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
    Patent number: 9452197
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: September 27, 2016
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Variants derived from ActRIIB
    Patent number: 9399669
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: July 26, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
    Publication number: 20160199458
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: John Knopf, Jasbir Seehra
  • Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumor
    Patent number: 9353356
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: May 31, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS
    Publication number: 20160120939
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 9, 2015
    Publication date: May 5, 2016
    Inventors: John Knopf, Jasbir Seehra
  • CERBERUS/COCO DERIVATIVES AND USES THEREOF
    Publication number: 20160115209
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 28, 2016
    Inventors: John Knopf, Jasbir Seehra
  • ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS
    Publication number: 20160108379
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Application
    Filed: August 26, 2015
    Publication date: April 21, 2016
    Inventors: John Knopf, Jasbir Seehra
  • METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS
    Publication number: 20160046690
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subject having an anemia and subjects have an ineffective erythropoiesis disorder.
    Type: Application
    Filed: March 20, 2015
    Publication date: February 18, 2016
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • Methods of promoting fat loss comprising administering an ALK7 inhibitor
    Patent number: 9255137
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: February 9, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide
    Patent number: 9163075
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: October 20, 2015
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ACTRIIB-FC polynucleotides, polypeptides, and compositions
    Patent number: 9138459
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: September 22, 2015
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20150183849
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: November 7, 2014
    Publication date: July 2, 2015
    Inventors: JASBIR SEEHRA, JOHN KNOPF, RAVINDRA KUMAR, ERIK VOGAN
  • Cerberus/Coco derivatives and uses thereof
    Patent number: 9045553
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 2, 2015
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20150010555
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: April 24, 2014
    Publication date: January 8, 2015
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar
  • Compositions and methods for increasing serum half-life
    Patent number: 8883982
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 11, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar, Erik Vogan
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20140328845
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: April 1, 2014
    Publication date: November 6, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
    Publication number: 20140227254
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Application
    Filed: December 27, 2013
    Publication date: August 14, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Uses of Cerberus and derivatives thereof
    Patent number: 8796199
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: August 5, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
    Publication number: 20140205600
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 24, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra
  • TREATMENT OF CANCER WITH ALK1 ANTAGONISTS
    Publication number: 20140193425
    Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.
    Type: Application
    Filed: October 4, 2013
    Publication date: July 10, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman